var data={"title":"Treatment protocols for non-small cell lung cancer","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment protocols for non-small cell lung cancer</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-non-small-cell-lung-cancer/contributors\" class=\"contributor contributor_credentials\">Tim Brenner, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-non-small-cell-lung-cancer/contributors\" class=\"contributor contributor_credentials\">Shrina Duggal, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-non-small-cell-lung-cancer/contributors\" class=\"contributor contributor_credentials\">Jim Natale, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-non-small-cell-lung-cancer/contributors\" class=\"contributor contributor_credentials\">Scott M Wirth, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-non-small-cell-lung-cancer/contributors\" class=\"contributor contributor_credentials\">John W Mucenski, PharmD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-non-small-cell-lung-cancer/contributors\" class=\"contributor contributor_credentials\">Sadhna R Vora, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-non-small-cell-lung-cancer/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 27, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H6926423\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with non-small cell lung cancer. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with non-small cell lung cancer. Additional regimens may be added over time, particularly as treatment for non-small cell lung cancer evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with non-small cell lung cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=systemic-therapy-for-the-initial-management-of-advanced-non-small-cell-lung-cancer-without-a-driver-mutation\" class=\"medical medical_review\">&quot;Systemic therapy for the initial management of advanced non-small cell lung cancer without a driver mutation&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer\" class=\"medical medical_review\">&quot;Adjuvant systemic therapy in resectable non-small cell lung cancer&quot;</a>.)</p><p/><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class=\"headingAnchor\" id=\"H119318348\"><span class=\"h1\">REGIMENS</span></p><p class=\"headingAnchor\" id=\"H936242762\"><span class=\"h2\">Carboplatin plus docetaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F69824\" class=\"graphic graphic_table graphicRef69824 \">table 1</a>)</p><p class=\"headingAnchor\" id=\"H112737105\"><span class=\"h2\">Carboplatin plus nanoparticle albumin-bound paclitaxel (nabpaclitaxel)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F95755\" class=\"graphic graphic_table graphicRef95755 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H936242787\"><span class=\"h2\">Carboplatin plus pemetrexed</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F81778\" class=\"graphic graphic_table graphicRef81778 \">table 3</a>)</p><p class=\"headingAnchor\" id=\"H936242812\"><span class=\"h2\">Cetuximab, vinorelbine, and cisplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F65122\" class=\"graphic graphic_table graphicRef65122 \">table 4</a>)</p><p class=\"headingAnchor\" id=\"H936242837\"><span class=\"h2\">Cisplatin plus pemetrexed</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F67209\" class=\"graphic graphic_table graphicRef67209 \">table 5</a>)</p><p class=\"headingAnchor\" id=\"H936242862\"><span class=\"h2\">Gemcitabine plus carboplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F54959\" class=\"graphic graphic_table graphicRef54959 \">table 6</a>)</p><p class=\"headingAnchor\" id=\"H936242887\"><span class=\"h2\">Gemcitabine plus cisplatin (GC)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F64774\" class=\"graphic graphic_table graphicRef64774 \">table 7</a>)</p><p class=\"headingAnchor\" id=\"H936242937\"><span class=\"h2\">Paclitaxel carboplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F56125\" class=\"graphic graphic_table graphicRef56125 \">table 8</a>)</p><p class=\"headingAnchor\" id=\"H936242912\"><span class=\"h2\">Paclitaxel, carboplatin, and bevacizumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F76013\" class=\"graphic graphic_table graphicRef76013 \">table 9</a>)</p><p class=\"headingAnchor\" id=\"H936242962\"><span class=\"h2\">Vinorelbine plus cisplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F59705\" class=\"graphic graphic_table graphicRef59705 \">table 10</a>)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 85689 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H6926423\" id=\"outline-link-H6926423\">INTRODUCTION</a></li><li><a href=\"#H119318348\" id=\"outline-link-H119318348\">REGIMENS</a><ul><li><a href=\"#H936242762\" id=\"outline-link-H936242762\">Carboplatin plus docetaxel</a></li><li><a href=\"#H112737105\" id=\"outline-link-H112737105\">Carboplatin plus nanoparticle albumin-bound paclitaxel (nabpaclitaxel)</a></li><li><a href=\"#H936242787\" id=\"outline-link-H936242787\">Carboplatin plus pemetrexed</a></li><li><a href=\"#H936242812\" id=\"outline-link-H936242812\">Cetuximab, vinorelbine, and cisplatin</a></li><li><a href=\"#H936242837\" id=\"outline-link-H936242837\">Cisplatin plus pemetrexed</a></li><li><a href=\"#H936242862\" id=\"outline-link-H936242862\">Gemcitabine plus carboplatin</a></li><li><a href=\"#H936242887\" id=\"outline-link-H936242887\">Gemcitabine plus cisplatin (GC)</a></li><li><a href=\"#H936242937\" id=\"outline-link-H936242937\">Paclitaxel carboplatin</a></li><li><a href=\"#H936242912\" id=\"outline-link-H936242912\">Paclitaxel, carboplatin, and bevacizumab</a></li><li><a href=\"#H936242962\" id=\"outline-link-H936242962\">Vinorelbine plus cisplatin</a></li></ul></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/85689|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/69824\" class=\"graphic graphic_table\">- Carboplatin plus docetaxel for adv non-small cell lung cancer</a></li><li><a href=\"image.htm?imageKey=ONC/95755\" class=\"graphic graphic_table\">- Carbo plus nab-paclitaxel advanced NSCLC</a></li><li><a href=\"image.htm?imageKey=ONC/81778\" class=\"graphic graphic_table\">- Carboplatin plus pemetrexed for non-small cell lung cancer</a></li><li><a href=\"image.htm?imageKey=ONC/65122\" class=\"graphic graphic_table\">- Cetuximab vinorelbine and cisplatin chemotherapy for NSCLC</a></li><li><a href=\"image.htm?imageKey=ONC/67209\" class=\"graphic graphic_table\">- Cisplatin plus pemetrexed NSCLC regimen</a></li><li><a href=\"image.htm?imageKey=ONC/54959\" class=\"graphic graphic_table\">- Gemcitabine plus carboplatin for non-small cell lung cancer</a></li><li><a href=\"image.htm?imageKey=ONC/64774\" class=\"graphic graphic_table\">- Gemcitabine plus cisplatin regimen for NSCLC</a></li><li><a href=\"image.htm?imageKey=ONC/56125\" class=\"graphic graphic_table\">- Paclitaxel and carboplatin for NSCLC</a></li><li><a href=\"image.htm?imageKey=ONC/76013\" class=\"graphic graphic_table\">- Paclitaxel-carboplatin-bevacizumab chemotherapy for NSCLC</a></li><li><a href=\"image.htm?imageKey=ONC/59705\" class=\"graphic graphic_table\">- Adjuvant vinorelbine plus cisplatin regimen for NSCLC</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer\" class=\"medical medical_review\">Adjuvant systemic therapy in resectable non-small cell lung cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-therapy-for-the-initial-management-of-advanced-non-small-cell-lung-cancer-without-a-driver-mutation\" class=\"medical medical_review\">Systemic therapy for the initial management of advanced non-small cell lung cancer without a driver mutation</a></li></ul></div></div>","javascript":null}